MedTrace Logo

HepaSphere™ Microspheres Prospective Registry

NCT04866290 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 105

Last updated 2023-04-03

Study results available
· View outcomes & findings →

Summary

HepaSphere™ Microspheres loaded with irinotecan received CE mark for the indication of use in embolization of metastatic colorectal cancer (mCRC) to the liver in 2015.

The purpose of this registry is to demonstrate the safety and efficacy of HepaSphere Microspheres loaded with irinotecan for the treatment of colorectal liver metastasis and add to the understanding of the use and value of this treatment in 'real life' usage conditions.

Conditions

Interventions

DEVICE

HepaSphere Microspheres

Sponsors & Collaborators

  • Merit Medical Systems, Inc.

    lead INDUSTRY

Principal Investigators

  • Katerina Malagari, MD · Evgenidio Hospital/ATTIKO Hospital

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-22
Primary Completion
2021-06-30
Completion
2021-06-30

Countries

  • France
  • Greece

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04866290 on ClinicalTrials.gov